U.S. FDA Fast Track Designation Granted for Envafolimab in Soft Tissue Sarcoma Subtypes
Simcere Ranked Among Top 100 China Pharma Innovation Enterprise 2022 released by Healthcare Executive
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group
COSELA® Clinical Data Disclosed at WCLC 2022, Myeloprotection Effect in Chinese Patient Confirmed by TRACES Study
COSELA®, the World's First Comprehensive Myeloprotection Drug against Chemotherapy Damage, Wins Approval in China
The Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patient with Colorectal Cancer Has Completed the Enrollment of All Subjects
Latest Clinical Data regarding ENDOSTAR and Trilaciclib Presented at the 2022 ASCO
Simcere Releases 2021 Environmental, Social and Governance (ESG) Report
SIM0335, Simcere's Investigational Drug for Psoriasis Entered Phase II Clinical Trial and has completed the first patient enrollment